The case for HIV prevention and treatment has been well established, and global stakeholders are working to expand access to both for PLWHIV and those at risk. However, despite the known benefits of existing HIV therapies, there are disproportionate gaps in uptake and adherence, particularly in vulnerable and under-served populations. New innovations that eliminate barriers to adherence and cater to patient needs – such as long-acting treatment, injectables, and implants – will be critical to not only support currently underserved patients, but to ensure cost-effectiveness and longer term cost savings for health systems. This session will examine the following topics: Why is it important for governments to prioritize investments in new HIV innovations now? How do we ensure governments prioritize these investments in the face of competing health priorities, and ensure adequate access to the 'newer at-risk' populations?